Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

被引：0
|
作者：
Feng Guo
Stephen P. Letrent
Pamela N. Munster
Carolyn D. Britten
Karen Gelmon
Anthony W. Tolcher
Amarnath Sharma
机构：
[1] Pfizer Global Research and Development,Department of Oncology
[2] Pfizer Global Research and Development,Department of Oncology
[3] H. Lee Moffitt Cancer Center and Research Institute,Department of Interdisciplinary Oncology, Experimental Therapeutics Program
[4] University of California at Los Angeles,Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine
[5] Vancouver Cancer Center,British Columbia Cancer Agency
[6] Cancer Therapy and Research Center,Institute for Drug Development
[7] Pfizer Global Research and Development,Department of Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
HER2 tyrosine kinase inhibitor; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 109
页数：12
相关论文
共 17 条
  • [1] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Guo, Feng
    Letrent, Stephen P.
    Munster, Pamela N.
    Britten, Carolyn D.
    Gelmon, Karen
    Tolcher, Anthony W.
    Sharma, Amarnath
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 97 - 109
  • [2] Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
    Feng, Bo
    Xu, Jinghai J.
    Bi, Yi-An
    Mireles, Rouchelle
    Davidson, Ralph
    Duignan, David B.
    Campbell, Scott
    Kostrubsky, Vsevolod E.
    Dunn, Margaret C.
    Smith, Arthur R.
    Wang, Huifen F.
    TOXICOLOGICAL SCIENCES, 2009, 108 (02) : 492 - 500
  • [3] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian
    Cao, Junning
    Li, Jin
    Zhang, Yifan
    Chen, Zhiyu
    Peng, Wei
    Sun, Si
    Zhao, Naiqing
    Wang, Jiachen
    Zhong, Dafang
    Zhang, Xiaofang
    Zhang, Jing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [4] Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
    Kourie, Hampig Raphael
    Chaix, Marie
    Gombos, Andrea
    Aftimos, Phillippe
    Awada, Ahmad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) : 947 - 957
  • [5] Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
    Li, Xin
    Yang, Changyong
    Wan, Hong
    Zhang, Ge
    Feng, Jun
    Zhang, Lei
    Chen, Xiaoyan
    Zhong, Dafang
    Lou, Liguang
    Tao, Weikang
    Zhang, Lianshan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 110 : 51 - 61
  • [6] Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
    Zhang, Tongtong
    Li, Qing
    Chen, Shanshan
    Luo, Yang
    Fan, Ying
    Xu, Binghe
    ONCOTARGET, 2017, 8 (22) : 36750 - 36760
  • [7] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Sun, Yongkun
    Niu, Wei
    Du, Feng
    Du, Chunxia
    Li, Shuting
    Wang, Jinwan
    Li, Li
    Wang, Fengqing
    Hao, Yu
    Li, Chuan
    Chi, Yihebali
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 9
  • [8] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Yongkun Sun
    Wei Niu
    Feng Du
    Chunxia Du
    Shuting Li
    Jinwan Wang
    Li Li
    Fengqing Wang
    Yu Hao
    Chuan Li
    Yihebali Chi
    Journal of Hematology & Oncology, 9
  • [9] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    F A L M Eskens
    C H Mom
    A S T Planting
    J A Gietema
    A Amelsberg
    H Huisman
    L van Doorn
    H Burger
    P Stopfer
    J Verweij
    E G E de Vries
    British Journal of Cancer, 2008, 98 : 80 - 85
  • [10] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    Eskens, Falm
    Mom, C. H.
    Planting, A. S. T.
    Gietema, J. A.
    Amelsberg, A.
    Huisman, H.
    van Doorn, L.
    Burger, H.
    Stopfer, P.
    Verweij, J.
    de Vries, Ege
    BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 80 - 85
12